FDA.reportPublic FDA data

Emrelis 100 MG Injection

RxCUI
2714251
RxNorm name
Emrelis 100 MG Injection
Display name
Emrelis 100 MG Injection
Full name
Emrelis 100 MG Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:18

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761384Emrelistelisotuzumab vedotin-tllv351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EMRELISTELISOTUZUMAB VEDOTINAbbVie Inc.bc04f980-3957-4e35-ab81-8ec2ffe872152025-05-25Warnings, Adverse reactionsExact identifier
rxcui: 2714251

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
bc04f980-3957-4e35-ab81-8ec2ffe87215Emrelis 100 MG InjectionPSN3These highlights do not include all the information needed to use EMRELIS safely and effectively. See full prescribing information for EMRELIS. EMRELIS™ (telisotuzumab vedotin-tllv) for injection, for intravenous use Initial U.S. Approval: 202520250525
bc04f980-3957-4e35-ab81-8ec2ffe87215Emrelis 100 MG InjectionSY3These highlights do not include all the information needed to use EMRELIS safely and effectively. See full prescribing information for EMRELIS. EMRELIS™ (telisotuzumab vedotin-tllv) for injection, for intravenous use Initial U.S. Approval: 202520250525
bc04f980-3957-4e35-ab81-8ec2ffe87215telisotuzumab vedotin-tllv 100 MG Injection [Emrelis]SBD3These highlights do not include all the information needed to use EMRELIS safely and effectively. See full prescribing information for EMRELIS. EMRELIS™ (telisotuzumab vedotin-tllv) for injection, for intravenous use Initial U.S. Approval: 202520250525